LumiThera is a medical device company at the forefront in the development of photobiomodulation (PBM) treatment protocols for patients with dry AMD.
Age-related macular degeneration (AMD) is the leading cause of blindness in adults over 65. There are two forms of AMD: dry and wet. Approximately 90% of patients with AMD have the dry form and 10% have the wet form.
CAUTION Investigational device. Limited by Federal (or United States) law to investigational use.
-
About Us
Developing
treatments
to preserve &
improve vision -
Products
Developing PBM
devices to treat ocular
diseases and disorders -
The Science
Learn about the
science supporting
the use of PBM -
Research
Learn about the
ongoing clinical studies